Knowledge-Based Company Meets Needs for Cutaneous Leishmaniasis Medicine in Iran

According to a report by the Iranian Ministry of Health and Medical Education, Alireza Akhawan Farid, the managing director of the knowledge-based company addressed a ceremony held in Isfahan city with the head of the Iran Food and Drug Administration (IFDA) in attendance and said that the development and production of high-risk drugs in Isfahan's knowledge-based pharmaceutical company has begun.

“This pharmaceutical company was built in 2019 with the support of the Iran National Innovation Fund (INIF) with an investment of 150 billion Tomans in an area over 1,500 square meters based on the latest optimal standards for the production of pharmaceutical products,” he said.

Stating that two knowledge-based products were unveiled in the ceremony, he noted that, “By acquiring the knowhow of the production of leishmaniasis (which is called Salk in Iran) medicine, the company has saved the country $1.5 million by domestically producing the medicine and preventing the amount to be spent on importing it.

Skin ulcers caused by leishmaniasis are not transmitted from one person to another. Cutaneous leishmaniasis occurs in exposed skin areas susceptible to sandfly bites and presents as a papule that gradually expands into an ulcerative plaque. For example, touching the ulcers on the hands and faces of children playing together can transmit the parasite to one another..

4155/i